Stephen F. Betz - Feb 1, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Feb 1, 2022
Transactions value $
-$58,681
Form type
4
Date filed
2/3/2022, 03:30 PM
Previous filing
Jan 20, 2022
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common stock Sale -$58.7K -3.12K -2.41% $18.79 127K Feb 1, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 Includes 954 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2021 by the Reporting Person.